Hemostatic powder bests standard endoscopic treatment for Hemostasis in malignant GI bleeding.

New research revealed that malignant gastrointestinal bleeding can be better controlled by using TC-325 hemostatic powder as it achieves greater immediate hemostasis and also has lower 30-day rebleeding rates when compared to contemporary standard endoscopic treatment. The study was published in the journal Gastroenterology. 

Gastrointestinal (GI) bleeding is the major global cause of morbidity and mortality. In recent years its incidence has steadily increased. As there is an immense necessity to control bleeding, hemostatic agents have been introduced that control bleeding effectively. But there is no sufficient data on the role of hemostatic powders when managing patients with malignant gastrointestinal (GI) bleeding due to varying guidelines and low-quality evidence. Hence researchers conducted a patient- and outcome-assessor-blinded multicenter randomized controlled trial to assess the role of hemostatic powders on GI bleeding. 

TC-325 alone or standard endoscopic therapy (SET) was randomly assigned to patients who presented with active bleeding from an upper or lower GI lesion believed to be malignant at index endoscopy between June 2019 and January 2022. 30-day rebleeding was the main goal, with rapid hemostasis and other clinically significant outcomes serving as supplementary targets.